Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-11-24-Speech-3-957"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20101124.15.3-957"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Regulation (EC) No 726/2004 lays down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishes a European Medicines Agency. The amendment to Directive 2001/83/EC emphasises better information for patients, especially in relation to the distinction between information and advertising. Following this amendment, the regulation, for its part, should be amended so that certain items of information on the products it covers can also be subjected to prior monitoring by the European Medicines Agency. With this aim in mind, the European Commission has tabled a proposal to amend the regulation, concerning the dissemination to the general public of information on prescription-only medicinal products for human use. The European Parliament, called on to express an opinion on the proposal, has tabled a number of amendments to the European Commission’s text. These are the reasons that have led me to vote in favour of the resolution amending Directive 2001/83/EC. These two sets of legislation work hand in hand to improve information to patients on the medicines that are issued to them."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples